Dashboard
Manage Tickers

CNTACentessa Pharmaceuticals plc

Nasdaq centessa.com


$ 15.09 $ 1.35 (9.82 %)    

Thursday, 12-Sep-2024 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.99 $ 4.60 (0.98 %)
DIA $ 411.97 $ 2.70 (0.66 %)
SPY $ 558.49 $ 4.67 (0.84 %)
TLT $ 100.12 $ -0.47 (-0.47 %)
GLD $ 236.34 $ 4.08 (1.76 %)
$ 15.1
$ 14.03
-- x --
-- x --
$ 14.03 - $ 15.24
$ 5.15 - $ 17.25
1,953,536
na
1.65B
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

centessa-pharmaceuticals-announces-150m-proposed-public-offering-of-american-depositary-shares
Centessa Pharmaceuticals Announces $150M P...
09/11/2024 20:05:28

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines...

centessa-pharmaceuticals-files-for-mixed-shelf-size-not-disclosed
Centessa Pharmaceuticals Files For Mixed S...
09/11/2024 20:03:41

- SEC Filing

guggenheim-maintains-buy-on-centessa-pharmaceuticals-raises-price-target-to-24
Guggenheim Maintains Buy on Centessa Pharm...
09/11/2024 16:45:01

Guggenheim analyst Debjit Chattopadhyay maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price tar...

jefferies-maintains-buy-on-centessa-pharmaceuticals-raises-price-target-to-19
Jefferies Maintains Buy on Centessa Pharma...
09/11/2024 15:41:25

Jefferies analyst Kelly Shi maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price target from $13...

sleep-disorder-focused-centessa-pharmaceuticals-unveils-interim-data-from-lead-program-in-acutely-sleep-deprived-healthy-volunteers
Sleep-Disorder Focused Centessa Pharmaceut...
09/10/2024 16:19:54

Centessa Pharmaceuticals revealed promising interim Phase 1 trial results for ORX750, demonstrating significant improvements in...

calavo-growers-posts-better-than-expected-earnings-joins-tesla-oracle-mission-produce-and-other-big-stocks-moving-higher-on-tuesday
Calavo Growers Posts Better-Than-Expected ...
09/10/2024 14:07:31

Core News & Articles
Market-Moving News for September 10th
09/10/2024 11:52:43

ORCL: 9% | Oracle shares are trading higher following better-than-expected Q1 financial results. JMP Securities upgraded the st...

centessa-pharmaceuticals-announced-interim-data-from-an-ongoing-phase-1-trial-of-orx750-in-acutely-sleep-deprived-healthy-volunteers-showing-clinically-meaningful-and-statistically-significant-improvements-in-mean-sleep-latency-at-the-first-two-doses-evaluated-vs-placebo
Centessa Pharmaceuticals Announced Interim...
09/10/2024 11:06:04

bmo-capital-maintains-outperform-on-centessa-pharmaceuticals-raises-price-target-to-20
BMO Capital Maintains Outperform on Centes...
09/09/2024 12:45:02

BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and raises the price...

centessa-pharmaceuticals-announces-late-breaking-poster-presentation-of-non-human-primate-data-for-orx142-at-sleep-europe-2024
Centessa Pharmaceuticals Announces Late-Br...
08/27/2024 12:13:23

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX14...

oppenheimer-reiterates-outperform-on-centessa-pharmaceuticals-maintains-14-price-target
Oppenheimer Reiterates Outperform on Cente...
08/14/2024 17:38:29

Oppenheimer analyst Francois Brisebois reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $14...

centessa-pharmaceuticals-q2-2024-gaap-eps-040-misses-039-estimate
Centessa Pharmaceuticals Q2 2024 GAAP EPS ...
08/13/2024 11:08:13

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estima...

oppenheimer-initiates-coverage-on-centessa-pharmaceuticals-with-outperform-rating-announces-price-target-of-14
Oppenheimer Initiates Coverage On Centessa...
07/18/2024 12:50:55

Oppenheimer analyst Francois Brisebois initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating...

morgan-stanley-maintains-equal-weight-on-centessa-pharmaceuticals-raises-price-target-to-11
Morgan Stanley Maintains Equal-Weight on C...
06/21/2024 14:14:07

Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Equal-Weight and raises the ...

centessa-pharma-taps-john-crowley-as-cfo-effective-june-10
Centessa Pharma Taps John Crowley, as CFO,...
06/10/2024 11:20:39

 Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicine...

reported-earlier-centessa-pharmaceuticals-prices-100m-public-offering-of-10810810-american-depositary-shares-at-925ads
Reported Earlier, Centessa Pharmaceuticals...
04/24/2024 06:18:39

announces-100m-proposed-public-offering-of-american-depositary-shares
Announces $100M Proposed Public Offering O...
04/23/2024 20:18:36

the-fda-has-cleared-centessa-pharmaceuticals-investigational-new-drug-application-to-initiate-a-phase-1-first-in-human-clinical-trial-of-orx750-for-narcolepsy
The FDA Has Cleared Centessa Pharmaceutica...
04/22/2024 11:09:07

bmo-capital-maintains-outperform-on-centessa-pharmaceuticals-maintains-15-price-target
BMO Capital Maintains Outperform on Centes...
04/01/2024 16:25:57

BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 pr...

centessa-pharmaceuticals-q4-eps-038-beats-048-estimate
Centessa Pharmaceuticals Q4 EPS $(0.38) Be...
03/28/2024 20:56:31

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION